Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Chemotherapy Medley
NCT03317496Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2017
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 2 trial of avelumab in non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), sponsored by Pfizer. Started Dec 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03317496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317496.